Orexo announces Canadian market launch for cancer pain drug
Uppsala/Tokyo – Orexo AB’s cancer pain treatment Abstral has reached the Canadian drug market. The Swedish drugmaker confirmed yesterday that Paladin Labs Inc have launched marketing of the sublingual formulation of fentanyl in breakthrough cancer pain, a global market worth US$1.5 billion. The distributor of pain killers had already gained a licence to market the drug in the Canadian market from UK-based Prostrakan Group plc in 2008. By February, the Canadian regulatory authority Health Canada had given marketing approval to the Scotland-based company which held the global distribution rights for Abstral until its recent acquisition by Japanese drugmaker Kyowa Hakko Kirin.